N(pro) fusion technology: On-column complementation to improve efficiency in biopharmaceutical production
S Schindler1, B Missbichler1, C Walther2
1Austrian Centre of Industrial Biotechnology, Muthgasse 11, 1190 Vienna, Austria.
Protein Expression and Purification
|December 22, 2015
Summary
A new N(pro) fusion technology splits the autoprotease N(pro) into two fragments for enhanced protein production. This system improves recombinant protein yield and reduces costs through efficient recycling of immobilized fragments.
Area of Science:
- Biotechnology
- Molecular Biology
- Protein Engineering
Background:
- N(pro) fusion technology is an efficient system for overexpressing proteins and peptides in Escherichia coli.
- Existing methods face limitations in tag size and recyclability, impacting overall productivity and cost-effectiveness.
Purpose of the Study:
- To develop a novel functional complementation system by splitting the N(pro) autoprotease into two fragments.
- To reduce the size of the expression tag and enhance the efficiency and recyclability of the N(pro) fusion system.
- To demonstrate the applicability of the system for various model proteins and its potential for large-scale recombinant protein production.
Main Methods:
- Splitting the N(pro) autoprotease into two functional fragments to create a complementation system.
- Testing the system's efficacy with model proteins of varying sizes, including a peptide, MCP-1, and lysozyme.
- Immobilizing the N-terminal fragment to a solid support to enable fragment recycling.
Main Results:
- The split N(pro) system successfully restored auto-proteolytic activity upon complementation of the fragments.
- The expression tag size was significantly reduced by 66%, from 168 to 58 amino acids.
- The system demonstrated functionality with diverse model proteins and enabled efficient recycling of the immobilized N-terminal fragment.
- Productivity was shown to increase up to 4-fold for batch refolding and potentially more for on-column refolding strategies.
Conclusions:
- The developed N(pro) complementation system offers a more efficient and cost-effective approach for recombinant protein and peptide production.
- The reduced tag size and recyclability of the immobilized fragment significantly enhance overall productivity.
- This technology holds substantial potential for improving yields and reducing costs in large-scale biopharmaceutical manufacturing.
Related Concept Videos
Production of Pharmaceuticals
51
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
51
Tagging and Fusion Proteins
8.7K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.7K
Upstream Processing
73
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
73
Hybridoma Technology
18.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.5K


